Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1465-1471
Published online before print June 12, 2003, doi: 10.1161/01.ATV.0000081635.96290.D3
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/8/1465    most recent
01.ATV.0000081635.96290.D3v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jarvik, G. P.
Right arrow Articles by Furlong, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jarvik, G. P.
Right arrow Articles by Furlong, C. E.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Carotid Artery Disease
Related Collections
Right arrow Primary prevention
Right arrow Transplantation
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1465.)
© 2003 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease

Gail P. Jarvik; Thomas S. Hatsukami; Chris Carlson; Rebecca J. Richter; Rachel Jampsa; Victoria H. Brophy; Sadie Margolin; Mark Rieder; Deborah Nickerson; Gerard D. Schellenberg; Patrick J. Heagerty; Clement E. Furlong

From the Departments of Medicine (Division of Medical Genetics) (G.P.J., R.J.R., R.J., V.H.B., S.M., C.E.F.), Epidemiology (G.P.J.), Genome Sciences (G.P.J., C.C., M.R., D.N., C.E.F.), Neurology (G.D.S.), and Biostatistics (P.J.H.), University of Washington, and the Puget Sound Veterans Affairs Health Care System (T.S.H., G.D.S.), Seattle, Wash.

Correspondence to Gail Jarvik, MD, PhD, University of Washington Medical Center, Division of Medical Genetics, Box 357720, Seattle, WA 98195-7720. E-mail pair{at}u.washington.edu

Objective— The effects of paraoxonase (PON1) activity and of genetic variation in the PON1 promoter and coding region on carotid artery disease (CAAD) were investigated.

Methods and Results— We identified functional promoter polymorphisms and examined their effects in a cohort with and without CAAD. We used the full sequences in 23 white subjects to determine the linkage disequilibrium (LD) structure of the PON1 region and to direct the grouping of haplotypes for disease association testing. There are several discrete regions of the PON1 gene with strong local LD, but the useful levels of LD do not extend across the entire gene. Indeed, PON1-162/-108/55/192 haplotype did not predict additional variation in PON1 activities compared with the 4 genotypes separately. PON1 hydrolysis activity predicted CAAD status, but this was not attributable to the promoter or coding region polymorphisms or haplotype or to the effects of smoking or statin use on PON1 activity.

Conclusions— PON1 does not have LD across the gene, and use of haplotypes in association studies should consider the LD structure. PON1 activity predicts CAAD, yet 4 functional polymorphisms do not. Additional investigations of genetic and environmental factors that influence PON1 activity as a risk factor for vascular disease are warranted.


Key Words: carotid • haplotype • oxidation • paraoxonase




This article has been cited by other articles:


Home page
Circ Cardiovasc GenetHome page
R. J. Richter, G. P. Jarvik, and C. E. Furlong
Determination of Paraoxonase 1 Status Without the Use of Toxic Organophosphate Substrates
Circ Cardiovasc Genet, December 1, 2008; 1(2): 147 - 152.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr, O. Alozie, M. W. Steffes, P. Kailash, J. H. Hayes, and M. D. Gross
Factors Associated with Paraoxonase Genotypes and Activity in a Diverse, Young, Healthy Population: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Clin. Chem., April 1, 2008; 54(4): 738 - 746.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
S. Lavi, J. P. McConnell, R. Lavi, G. W. Barsness, C. S. Rihal, G. D. Novak, L. O. Lerman, and A. Lerman
Association Between the Paraoxonase-1 192Q>R Allelic Variant and Coronary Endothelial Dysfunction in Patients With Early Coronary Artery Disease
Mayo Clin. Proc., February 1, 2008; 83(2): 158 - 164.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. Frikke-Schmidt, B. G. Nordestgaard, G. B. Jensen, R. Steffensen, and A. Tybjaerg-Hansen
Genetic Variation in ABCA1 Predicts Ischemic Heart Disease in the General Population
Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 180 - 186.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Van Eck, M. Hoekstra, R. B. Hildebrand, Y. Yaong, D. Stengel, J. K. Kruijt, W. Sattler, U. J.F. Tietge, E. Ninio, T. J.C. Van Berkel, et al.
Increased Oxidative Stress in Scavenger Receptor BI Knockout Mice With Dysfunctional HDL
Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2413 - 2419.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
D. L Rainwater, M. C Mahaney, J. L VandeBerg, and X. L. Wang
Vitamin E dietary supplementation significantly affects multiple risk factors for cardiovascular disease in baboons
Am. J. Clinical Nutrition, September 1, 2007; 86(3): 597 - 603.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. Gaidukov and D. S. Tawfik
The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity
J. Lipid Res., July 1, 2007; 48(7): 1637 - 1646.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. L. Goode, J. D. Potter, W. R. Bamlet, D. N. Rider, and J. Bigler
Inherited variation in carcinogen-metabolizing enzymes and risk of colorectal polyps
Carcinogenesis, February 1, 2007; 28(2): 328 - 341.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. L. Carty, P. Heagerty, K. Nakayama, E. C. McClung, J. Lewis, D. Lum, E. Boespflug, C. McCloud-Gehring, B. R. Soleimani, J. Ranchalis, et al.
Inflammatory Response After Influenza Vaccination in Men With and Without Carotid Artery Disease
Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2738 - 2744.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. Gaidukov, M. Rosenblat, M. Aviram, and D. S. Tawfik
The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux
J. Lipid Res., November 1, 2006; 47(11): 2492 - 2502.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
V. L. Stevens, C. Rodriguez, A. L. Pavluck, M. J. Thun, and E. E. Calle
Association of Polymorphisms in the Paraoxonase 1 Gene with Breast Cancer Incidence in the CPS-II Nutrition Cohort.
Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1226 - 1228.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
F. Marchegiani, M. Marra, L. Spazzafumo, R. W. James, M. Boemi, F. Olivieri, M. Cardelli, L. Cavallone, A. R. Bonfigli, and C. Franceschi
Paraoxonase activity and genotype predispose to successful aging.
J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 541 - 546.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
C. S. Carlson, P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al.
TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease
J. Lipid Res., May 1, 2006; 47(5): 1014 - 1024.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
D. M. Shih, H. R. Kast-Woelbern, J. Wong, Y.-R. Xia, P. A. Edwards, and A. J. Lusis
A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids
J. Lipid Res., February 1, 2006; 47(2): 384 - 392.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
P. M. Erlich, K. L. Lunetta, L. A. Cupples, M. Huyck, R. C. Green, C. T. Baldwin, L. A. Farrer, and for the MIRAGE Study Group
Polymorphisms in the PON gene cluster are associated with Alzheimer disease
Hum. Mol. Genet., January 1, 2006; 15(1): 77 - 85.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al.
The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status
J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. Chen, W. Chan, S. Wallenstein, G. Berkowitz, and J. G. Wetmur
Haplotype-Phenotype Relationships of Paraoxonase-1
Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 731 - 734.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. D. Nguyen and D.-E. Sok
Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids
J. Lipid Res., December 1, 2004; 45(12): 2211 - 2220.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Kontush, E. C. de Faria, S. Chantepie, and M. J. Chapman
Antioxidative Activity of HDL Particle Subspecies Is Impaired in Hyperalphalipoproteinemia: Relevance of Enzymatic and Physicochemical Properties
Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 526 - 533.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. N. La Du
Future Studies of Low-Activity PON1 Phenotype Subjects May Reveal How PON1 Protects Against Cardiovascular Disease
Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1317 - 1318.
[Full Text] [PDF]